MedPath

HEMANEXT INC.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

5

Active:0
Completed:2

Trial Phases

2 Phases

Phase 2:2
Not Applicable:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Not Applicable
2 (50.0%)
Phase 2
2 (50.0%)

Hypoxic Red Blood Cells in Sickle Cell Anemia

Not Applicable
Not yet recruiting
Conditions
Sickle Cell Anaemia
Sickle Cell Anemia Crisis
Sickle Cell Anemia in Children
Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)
First Posted Date
2024-12-19
Last Posted Date
2024-12-19
Lead Sponsor
Hemanext
Target Recruit Count
48
Registration Number
NCT06743113
Locations
🇺🇸

New England Sickle Cell Institute, University of Connecticut, Farmington, Connecticut, United States

🇺🇸

Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States

🇺🇸

Emory University School of Medicine, Atlanta, Georgia, United States

and more 3 locations

Comparison of Hemanext ONE® System and Conventional Red Blood Cell Transfusion

Not Applicable
Recruiting
Conditions
Hematologic Neoplasms
First Posted Date
2024-11-13
Last Posted Date
2024-12-10
Lead Sponsor
Hemanext
Target Recruit Count
24
Registration Number
NCT06685848
Locations
🇳🇴

Haukeland University Hospital, Bergen, Norway

Hypoxic Red Blood Cells for Burns and Hematological Malignancies at Haukeland University Hospital

Completed
Conditions
Hematologic Neoplasms
Burns
First Posted Date
2022-09-22
Last Posted Date
2025-05-18
Lead Sponsor
Hemanext
Target Recruit Count
22
Registration Number
NCT05549232
Locations
🇳🇴

Haukeland University Hospital, Bergen, Norway

Clinical Investigation to Evaluate the Hemanext® Red Blood Cell Processing System for Extended Storage of Leukoreduced Red Blood Cells

Phase 2
Withdrawn
Conditions
Whole Blood Donations and Leukoreduction
First Posted Date
2020-06-05
Last Posted Date
2020-08-03
Lead Sponsor
Hemanext
Registration Number
NCT04418934
Locations
🇺🇸

Hoxworth Blood Center, University of Cincinnati, Cincinnati, Ohio, United States

🇺🇸

American Red Cross Mid-Atlantic Research Facility, Norfolk, Virginia, United States

Clinical Investigation to Evaluate the Hemanext® Oxygen Reduction System - Pivotal Trial

Phase 2
Completed
Conditions
Whole Blood Donation and Leukoreduction
First Posted Date
2017-10-04
Last Posted Date
2020-06-23
Lead Sponsor
Hemanext
Target Recruit Count
100
Registration Number
NCT03301779
Locations
🇺🇸

Hoxworth Blood Center, University of Cincinnati, Cincinnati, Ohio, United States

🇺🇸

American Red Cross Mid-Atlantic Research Facility, Norfolk, Virginia, United States

🇺🇸

Blood Center of Wisconsin, Milwaukee, Wisconsin, United States

News

No news found
© Copyright 2025. All Rights Reserved by MedPath